A 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED STUDY OF GINKO BILOBA AUGMENTATION

银杏叶增强作用的 12 周双盲安慰剂对照研究

• 批准号: 7606161
• 负责人: FREDA CHEUNG
• 金额: $ 1.33万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606161
• 关键词: Brain; Computer Retrieval of Information on Scientific Projects Database; Dose; Double-Blind Method; Funding; Ginkgo biloba; Ginkgo biloba extract; Grant; Institution; Measures; Memory; Neurocognitive; Performance; Pharmaceutical Preparations; Placebo Control; Placebos; Randomized; Research; Research Personnel; Resistance; Resources; Schizophrenia; Source; Standards of Weights and Measures; Symptoms; United States National Institutes of Health; Week; design; improved; instrument; placebo controlled study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To examine whether standardized extracts of Ginko biloba (Gb) might be a useful added agent in treating symptoms of schizophrenia, particularly negative symptoms and/or improve their brain function and memory. The study will use a double-blind, randomized, placebo-controlled design, and will include 100 subjects with treatment resistant schizophrenia. Subjects will be randomized to receive either a standard dose of Gb or placebo for 12 weeks in addition to continuing their treatment with anti psychotic medications that have been judged as optimal prior to entering the study. Standard assessment instruments will be used for measuring changes in symptoms (both positive and negative), neurocognitive performance and functioning status. Assessments will be done at baseline, and at the end of weeks 2,4,6 and 12.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 研究标准银杏叶提取物(GB)在治疗精神分裂症症状，特别是阴性症状和/或改善他们的大脑功能和记忆方面是否可能是有用的附加剂。这项研究将采用双盲、随机、安慰剂对照设计，将包括100名难治性精神分裂症患者。受试者将被随机接受标准剂量的GB或安慰剂治疗12周，此外，在进入研究之前，他们还将继续接受被认为是最佳的抗精神病药物治疗。标准评估工具将用于衡量症状(包括阳性和阴性)、神经认知表现和功能状态的变化。评估将在基线以及第2、4、6和12周结束时进行。